Journal article
Emerging Targets of Diuretic Therapy
Clinical pharmacology and therapeutics, Vol.102(3), pp.420-435
09/2017
DOI: 10.1002/cpt.754
PMCID: PMC5546989
PMID: 28560800
Abstract
Diuretics are commonly prescribed for treatment in patients with hypertension, edema, or heart failure. Studies on hypertensive and salt‐losing disorders and on urea transporters have contributed to better understanding of mechanisms of renal salt and water reabsorption and their regulation. Proteins involved in the regulatory pathways are emerging targets for diuretic and aquaretic therapy. Integrative high‐throughput screening, protein structure analysis, and chemical modification have identified promising agents for preclinical testing in animals. These include WNK‐SPAK inhibitors, ClC‐K channel antagonists, ROMK channel antagonists, and pendrin and urea transporter inhibitors. We discuss the potential advantages and side effects of these potential diuretics.
Details
- Title: Subtitle
- Emerging Targets of Diuretic Therapy
- Creators
- C‐J Cheng - Division of Nephrology, Tri‐Service General Hospital, National Defense Medical CenterA R Rodan - Division of Nephrology, University of UtahC‐L Huang - Division of Nephrology, University of Texas Southwestern Medical Center
- Resource Type
- Journal article
- Publication Details
- Clinical pharmacology and therapeutics, Vol.102(3), pp.420-435
- DOI
- 10.1002/cpt.754
- PMID
- 28560800
- PMCID
- PMC5546989
- NLM abbreviation
- Clin Pharmacol Ther
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- Number of pages
- 16
- Grant note
- National Health Research Institutes of Taiwan (NHRI‐EX106‐10323SC) National Institutes of Health of the United States (DK110358; DK109887; DK100605) American Heart Association of the Unites States (16CSA28530002) Tri‐Service General Hospital of Taiwan (TSGH‐C106‐94) MOST of Taiwan (MOST 103‐2628‐B‐016‐001‐MY3)
- Language
- English
- Date published
- 09/2017
- Academic Unit
- Nephrology; Internal Medicine
- Record Identifier
- 9984094763902771
Metrics
15 Record Views